Genetec

Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research. The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.

Genea provides best-in-class innovation to drive the future of property technology. Our cutting-edge security, visitor management, submeter billing, and after-hours HVAC software have helped over 4,500 companies transform and streamline their operations. With the combination of advanced technology and customer-centric support, Genea has earned the trust of teams from Fortune 50 companies, corporate real estate, national healthcare systems, global enterprises, and more. Genea stays committed to providing innovative technology solutions. With new product features released every quarter, we help our customers achieve a more secure and efficient future. But unprecedented technology is only one part of success. At Genea, we stay committed to delivering the highest level of customer service and support to all our customers. Genea promises to treat each interaction with the transparency and teamwork customers deserve.

Genmab is an international biotechnology company that has been transforming cancer treatment for over two decades. Founded in 1999, Genmab has established itself as a leader in antibody therapeutics, with a proven track record of creating breakthrough medicines that improve patients' lives. The company has successfully developed multiple approved antibody therapeutics that are marketed globally, bringing innovative treatments to patients with cancer and other serious diseases. With headquarters in Denmark and offices across the Netherlands, United States, Japan, and the United Kingdom, Genmab operates as a truly global organization. The company's expertise spans the entire antibody development process, from discovery through commercialization, leveraging proprietary technology platforms to create differentiated therapeutics. Genmab's pipeline includes numerous investigational medicines in clinical development, reflecting the company's commitment to pushing the boundaries of antibody science to address unmet medical needs.

DNAnexus is the enterprise platform for precision health, transforming how genomic and multiomic data is managed, analyzed, and shared across the healthcare and life sciences industries. Founded in 2009 and building on 15 years of bioinformatics innovation, the company provides a secure, cloud-based platform that centralizes complex biological datasets and enables collaborative research at unprecedented scale. Trusted by leading pharmaceutical companies, academic medical centers, clinical diagnostic labs, and biobanks worldwide, DNAnexus processes petabytes of precision health data to accelerate scientific discovery and improve patient outcomes. The platform delivers comprehensive capabilities for ingesting, organizing, and analyzing multimodal data - from next-generation sequencing to real-world evidence - while maintaining clinical-grade security and compliance. DNAnexus powers the world's largest genomics initiatives, including partnerships with major biobanks and research consortia, enabling breakthroughs in drug development, precision medicine, and population health. By combining cloud computing infrastructure with deep domain expertise in computational biology, DNAnexus has established itself as the foundational technology layer for the precision health ecosystem, helping organizations translate vast biological datasets into actionable insights that advance human health.

At Cyngn, we believe innovation thrives in collaborative environments where diverse perspectives shape our autonomous technology. With under 100 employees, we operate with startup energy and the stability of a publicly-traded company. Our engineers deploy real autonomous vehicles - not test concepts - to factories and warehouses across North America, ensuring tangible impact from every line of code. We prioritize trust and creative collaboration, valuing every team member's input as the fuel for our breakthroughs. Our close-knit teams work directly with company leadership, gaining mentorship while building cutting-edge robotics that transform industrial operations today, not someday. We're a welcoming, diverse team of sharp thinkers and kind humans. Collaboration and trust drive our creative environment. At Cyngn, everyone's perspective matters - and that's what powers our innovation as we revolutionize material handling with DriveMod autonomous vehicles.

GenLogs builds the Freight Intelligence platform that delivers proprietary insights through a nationwide network of roadside sensors, commercial datasets, and open-source information. The company captures real-time data on millions of commercial trucks across America, providing unprecedented visibility into freight movement for logistics providers, insurance carriers, and law enforcement agencies. GenLogs applies counterterrorism principles developed by its founders - former U.S. intelligence officials - to combat cargo theft, freight fraud, and supply chain vulnerabilities. The platform has uniquely fingerprinted nearly 300,000 for-hire carriers and observed their trucks nearly one billion times, far exceeding traditional DOT inspection capabilities. GenLogs transforms how transportation data is captured, secured, and commercialized by operating at the intersection of edge sensing, computer vision, AI-driven analytics, and large-scale field deployment. The company serves three primary markets: freight brokers seeking trusted carrier capacity, insurance companies requiring fleet intelligence for underwriting and claims, and law enforcement agencies investigating cargo theft and smuggling. GenLogs has helped customers prevent millions in losses and recover over 1,000 stolen or misused trailers. The company aims to unlock $7 trillion of new global freight flows while fighting $30 billion of fraud and theft annually, establishing a new standard for freight intelligence in the United States.